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Abstract 
Three-dimensional multicellular tumor models are receiving an ever-growing focus as 
preclinical drug-screening platforms due to their potential to recapitulate major 
physiological features of human tumors in vitro. In line with this momentum, the 
technologies for assembly of 3D microtumors are rapidly evolving towards a 
comprehensive inclusion of tumor microenvironment elements. Customized spherically 
structured platforms, including microparticles and microcapsules, provide a robust and 
scalable technology to imprint unique biomolecular tumor microenvironment hallmarks 
into 3D in vitro models. Herein, a comprehensive overview of novel advances on the 
integration of tumor-ECM components and biomechanical cues into 3D in vitro models 
assembled in spherical shaped platforms is provided. Future improvements regarding 
spatiotemporal/mechanical adaptability, and degradability, during microtumors in vitro 3D 
culture are also critically discussed considering the realistic potential of these platforms to 
mimic the dynamic tumor microenvironment. From a global perspective, the production of 
3D multicellular spheroids with tumor ECM components included in spherical models will 
unlock their potential to be used in high-throughput screening of therapeutic compounds. It 
is envisioned, in a near future, that a combination of spherically structured 3D microtumor 
models with other advanced microfluidic technologies will properly recapitulate the flow 
dynamics of human tumors in vitro. 
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Abbreviations: Three-dimensional Multicellular Tumor Spheroids (3D-MCTS), Tumor Extracellular 
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Cells (MSCs), Poly-L-Lysine (PLL), Human Adipose-derived Stem Cells (hADSCs), Alkaline Phosphatase 
(ALP), Matrix Metalloproteinases (MMPs), Epithelial-to-Mesenchymal-Transition (EMT), Green 
Fluorescent Protein (GFP), Epidermal Growth Factor (EGF), Basic Fibroblast Growth Factor (bFGF), 
Platelet-Derived Growth Factor (PDGF), Hyaluronic Acid (HyA), Stromal Cell-Derived Factor Α (SDF-1α), 
Vascular Endothelial Growth Factor (VEGF), Bone Morphogenetic Protein 2 (BMP-2), Human Bone-
Marrow Derived Mesenchymal Stem Cells (hBM-MSCs), Decellularized Matrices (dECMs), Poly(ethylene 
glycol) (PEG), Polylactic Acid (PLA), Poly(Glycolic Acid) (PGA), Poly(Lactic-co-Glycolic Acid) (PLGA), 
Poly-ɛ-Caprolactone (PCL), Polyvinyl Alcohol (PVA), Polystyrene (PS), Cancer-Associated Fibroblasts 
(CAFs), Prostate Cancer Stem-Like Cells (PCa-CSCs), Human Umbilical Vein Endothelial Cells (HUVECs), 
Poly(ethylene glycol) Diacrylate (PEGDA), Hematoxylin-Eosin (H&E), Red Fluorescent Protein (RFP). 
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1. Introduction 
2D flat cell cultures of cancer cells remain the most commonly used in vitro 
platforms for screening anti-cancer therapeutics, despite their recognized inability for 
mimicking three-dimensional (3D) cellular organization and tumor proliferation kinetics 
[1–3]. Moreover, these in vitro models lack the ability to correctly mimic tumor stromal 
heterogeneity and tumor-ECM components. Adding to these limitations, nutrients, oxygen, 
and pH gradients are not recapitulated, resulting in a recognized inability to realistically 
mimic in vivo tumors [3]. Overcoming the shortcomings of conventional 2D cultures 
through the engineering of more robust in vitro models capable of simulating in vivo solid 
tumors, could improve the efficacy of anti-cancer drug discovery and biological 
performance screening [1]. The development of such models could contribute to reduce the 
number of false-positive results obtained during preclinical validation of novel compounds 
and improve the in vitro/in vivo correlation. 
In this context, three-dimensional (3D) in vitro models have been gaining 
increasing momentum in the field of drug-screening and cancer research, due to their 
improved ability for recapitulating the complexity of the tumor microenvironment (TME) 
[4,5]. 3D culture models are capable of recapitulating tumors cellular heterogeneity, cell-
cell interactions, and spatial architecture. In fact, the reproduction of such characteristics in 
3D promotes the establishment of nutrient, oxygen, and signaling factor gradients, as well 
as the establishment of unique gene expression patterns similar to those observed in in vivo 
solid tumors [6]. 
From the currently available in vitro tumor models, 3D multicellular tumor spheroid 
models (3D-MCTS) remain one of the most commonly explored [7,8]. Their relative ease 
of assembly, reproducibility, and the ability to capture cellular heterogeneity (e.g., co-
cultures of cancer-stromal cells), renders them suitable tumor surrogates for preclinical 
validation of novel therapeutic compounds [9]. Up to date, various 3D-MCTS in vitro 
models have been used to modulate the cellular components present in the TME of 
different tumors including those of breast [10], colon [11], pancreas [12] and lung [13]. 
However, most of these models still lack a complete representation of tumor-specific and 
disease stage-specific ECM. This is a critical component which is recognized to 
extensively influence cancer evolution through key biochemical and biomechanical cues 
[14,15]. 
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To overcome these limitations, various studies have attempted to include ECM 
mimetics in the form of spherically structured scaffolds, namely microparticles or 
microcapsules. These technologies have been extensively used in the field of tissue 
engineering and stem cell research [16–18], and offer further opportunities to mimic the 
complexity of the TME in vitro. In fact, this approach opens the possibility to study 
biochemical and tumor-ECM dependent mechanical cues through the inclusion of modular 
matrix-mimetic scaffolds [19]. The inclusion of tumor-ECM components in a 3D spherical 
geometry allows researchers to control various key parameters, such as: (i) pH, oxygen, 
and nutrient perfusion gradients, (ii) cell-cell interactions, (iii) morphology, and (iv) tumor 
models overall size. Importantly, previous studies have associated variations in 3D tumor 
microtissues size and morphology with variability in phenotype, gene expression profile, 
as well as with the degree of response to anti-cancer or anti-stromal therapeutics [20,21]. 
The integration of spherically structured scaffolds morphology into tumor modeling is 
herein demonstrated to not only allow an increased control over produced spheroids 
biophysical properties, but also to increase models’ reproducibility in terms of shape and 
size, both of which are major aspects that must be considered in drug screening assays. 
Furthermore, implementation of spherical designs facilitates incorporation of tumor-ECM 
components in well-established methodologies for spheroids analysis [22]. This unlocks 
the opportunity to model cell-ECM interactions and to evaluate the influence of ECM 
components inclusion in the response to anti-cancer therapeutics in a high-throughput 
compatible mode.  
On this focus, this review showcases and critically discusses the recent advances in 
the field of complex 3D in vitro tumor models’ assembly via spherical scaffolds. We begin 
by summarizing current scaffold-free and scaffold-based 3D microtumor production 
technologies and present up-to-date examples on the use of microparticles, microspheres, 
and microcapsules to assembly advanced 3D-MCTS. A critical perspective regarding 
future developments on new models that fully recapitulate in vitro the cellular and acellular 
components of the TME is also provided. 
2. In vitro 3D Models Production 
Ideally, 3D tumor models should be able to recapitulate the cell-cell and cell-tumor 
ECM crosstalk established during tumor progression. This communication is well 
recognized to contribute to the establishment of either pro-tumoral or anti-tumoral 
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microenvironments [23,24], depending on the type of cells and ECM properties. Such 
dichotomy is well portrayed by the communications that can be established between 
immune cells and mesenchymal stem cells (MSCs) present in the TME. In fact, MSCs-
immune cells communications can lead both to immunosuppression and promotion of 
angiogenesis, or to the increased recognition of cancer cells by infiltrating immune cells. 
Such crosstalk is precisely mediated by the release of anti- and pro-inflammatory cytokines 
and growth factors, which can exert different effects depending on their amount and 
combinations [25,26]. Therefore, to recapitulate human tumors, 3D models must mimic 
this dichotomy, as well as ECM mechanical properties, cells spatial arrangement, and 
spatiotemporal biochemical composition of the TME. In vitro 3D microtumors should also 
be produced to dynamically recapitulate specific disease stages (e.g., from proliferation to 
metastasis) under highly reproducible conditions, so as to assure a direct correlation 
between in vitro and in vivo data [27]. 
3D multicellular tumor models production methodologies can be divided into three 
major categories: (i) scaffold-based models which take advantage of diverse natural, or 
synthetic materials that aim to mimic in vivo tumor-ECM [28–30]; (ii) scaffold-free 
models, which take advantage of cells suspension or hanging-drop techniques for assembly 
of 3D-MCTS [31–34]; and (iii) combinatorial hybrid technologies such as 
microencapsulation or microparticle-based approaches, which seek to combine the cell-cell 
aggregation obtained in scaffold-free based methods with the ECM representing capacities 
of 3D scaffold-based platforms. The following sections will discuss the differences and 
common advantages/disadvantages of currently employed technologies for the 
establishment of 3D-MCTS. In section 3, a focus is provided on spherically structured 
assembly of 3D in vitro models as these technologies have potential to emulate the 
different components of in vivo tumors TME. 
2.1. Scaffold-free 3D Models Production 
Scaffold-free methods are based on the implementation of cell cultures under non-
adherent conditions (Figure 1). The main aim of this strategy is to promote the production 
of 3D spherical (spheroids) or more loosely aggregated microtissues (cellular aggregates) 
[35–37]. Despite scaffold-free models nomenclature remains non-regulated to date, in 
general terms it can be classified into three distinct categories: (i) multicellular tumor 
spheroid models (3D-MCTS), initially implemented in the 1970s by Sutherland and co-
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workers [38], (ii) organotypic multicellular spheroids (e.g., fragments of tumor tissue 
cultured in non-adherent conditions), and (iii) tissue-derived tumor spheres obtained by 
partial disruption of tumor tissues through mechanical and/or enzymatical dissociation 
[39]. These microtissues are easy to assemble, to culture in vitro, and have been 
extensively used in the field of 3D in vitro disease modeling for drug screening and more 
fundamental biology studies.  
Static-based, scaffold-free methods such as forced-floating or hanging-drop 
techniques allow the assembly of highly reproducible 3D-MCTS in terms of size and 
morphology [40,41]. These techniques employ super-hydrophobic surfaces, or for 
example, poly(2-hydroxyethyl methacrylate) [42], or agarose coated multiwell plates 
[31,43,44] (Figure 1), to prevent adhesion to culture plate surfaces and promote instead 
cell-cell interactions that lead to intercellular adhesion and aggregation [32]. These 3D-
MCTS can be formed either by monotypic or heterotypic co-cultures (e.g., comprising 
cancer and stromal cells) [45,46]. Over time, the newly formed 3D-MCTS start to secrete 
their own ECM, which increases their density and diminishes their size, further 
approaching these models to compact solid tumors similar to those obtained in vivo [47].  
Dynamic, stirring-based technologies can be grouped into two classes: (i) stirring 
tank bioreactors in which the culture media is internally impelled (e.g., by spinning 
blades), and (ii) rotational (microgravity) bioreactors [48] (Figure 1). Such methods take 
advantage of mechanical forces that maintain cells in continuous suspension during culture 
[35]. 
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Figure 1. Schematics of scaffold-free technologies used for 3D in vitro tumor spheroids assembly. Static technologies are 
useful to obtain 3D microtissue with highly reproducible sizes but are unable to mimic the mechanical forces that 
cells/cellular 3D aggregates experience when cultured under dynamic flow conditions. Image layout adapted from 
Picollet-D'hahan and co-workers [49], with permission from Elsevier. 
 
By comparison to stirred tank bioreactors, rotational (microgravity) bioreactors 
have the advantage that the internal flow is generated by rotation of the container and not 
through blade mechanisms, thus imparting a lower shear-stress to the cultivated cells [50].  
In comparison to static methods, stirring-based methodologies are able to 
effectively produce high amounts of 3D-MCTS, having the advantage of allowing easy 
culture medium exchange and modifications to cell culture conditions in situ [51]. 
However, regarding 3D aggregates reproducibility, stirring-based techniques lack a 
suitable level of control over 3D spheroids morphology and size, an important parameter 
that is generally present in static-based methodologies [52]. In fact, 3D spheroids and 
cellular aggregates obtained in bioreactors frequently exhibit variable shapes and density, 
leading to inconsistent responses to anti-cancer therapeutics [27,41]. Since cellular 
concentration is dictated for the entire batch, different internal dynamic flows can also 
result in aggregates with different sizes [53].  
The combination of stirring and forced adhesion methods could overcome such 
limitations. For example, one could combine hanging-drop technique to obtain highly 
uniform 3D spheroids, and then translocate them into bioreactors or microfluidic platforms 
for evaluating fluid dynamics influence [54]. Overall, the main advantages of scaffold-free 
combination with dynamic culture methods are: (i) the ease of manufacturing multiple and 
reproducible 3D microtissues per batch; (ii) the ability to maintain prolonged culture times; 
(iii) the ability to modify the culture media and growth conditions (e.g., media perfusion 
flow rate, nutrient starvation); and (iv) the ability examine 3D models evolution in time 
either by single direct analysis in situ [55], or by placing them in hanging-drop super-
hydrophobic, on-chip arrays [33,56]. In a study performed by Oliveira and co-workers 
[57], such super-hydrophobic surfaces were employed to produce osteosarcoma spheroid 
arrays for anti-cancer drug-screening. Superhydrophobic surfaces patterned with wettable 
spots were successfully applied for osteosarcoma cells (Saos-2) 3D spheroids formation, 
and allowed the establishment of dynamic platforms capable of simulating 
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chemotherapeutics clearance through means of dynamic media renewal [57]. In addition, 
these platforms were also recently explored by Oliveira and co-workers [58], for stem cell-
based tissue engineering. In this study, human adipose-derived stem cells (hADSCs) 3D 
spheroids were established under either direct or indirect co-culture with 2D cell layers. 
The cells were cultured in the flat microarray surface where a droplet of cells that formed 
the 3D spheroids was also formed. Co-culture of 3D hADSCs with 2D layers of HUVECs 
or Saos-2, resulted respectively in a significant decrease and slight increase in alkaline 
phosphatase (ALP) expression, an enzyme associated with hADSCs osteogenic 
differentiation, Therefore, such high-content imaging compatible, spheroid forming arrays, 
could be used in the future to study diverse stromal cells and 3D tumor spheroids direct or 
indirect interactions [58].  
2.2. Scaffold-Based 3D Models Production 
Tumor evolution in vivo is intimately correlated with the interactions between cells 
of the TME and their supporting ECM which provides both structural and signaling 
functions [59]. In a general perspective, the ECM is comprised mainly by fibronectin, 
collagen (types I-V), elastin, entactin, fibrillin, fibulin, vitronectin, laminin, as well as 
other glycoproteins and proteoglycans such as hyaluronic acid [60]. The exact composition 
of the ECM surrounding the primary tumor site can vary according to the type of tissue. 
Hence, the design of 3D in vitro models must take into account tissue, and patient, ECM 
specificity, since this variability can lead to different response rates to candidate anti-
cancer therapeutics [27]. Furthermore, during tumorigenesis, alterations in matrix 
composition and structure occur over time due to cancer and stromal cell-mediated ECM 
deposition or degradation (mainly through matrix metalloproteinases (MMP) enzymatic 
digestion (e.g., MMP-9, MMP-2). This matrix rearrangement often involves collagen 
deposition and matrix stiffening, a phenomenon that is associated to an increased 
metastatic potential [61]. Moreover, various reports indicate that increased hyaluronan 
deposition and degradation occurs in several cancers. Such increases angiogenesis, 
metastasis and possibly drug-resistance [62–64].  
It is this dynamic nature of the interactions established between all the cells in the 
tumor microenvironment and the surrounding ECM that scaffold-based tumor models aim 
to fully recapitulate. Scaffold-based 3D in vitro tumor models take advantage of natural, 
synthetic or hybrid biomaterials to culture cells in a TME-like milieu [19,35]. Each of 
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these classes presents its own advantages and disadvantages in mimicking in vivo tumors 
on an in vitro setting (Table 2). While naturally derived ECM mimetics have relatively low 
batch-to-batch reproducibility, scaffolds formulated with synthetic materials although more 
reproducible may require functionalization with bioactive molecules or inclusion of 
naturally-derived bioactive cues (e.g., peptides, adhesion proteins, etc), thus originating 
hybrid scaffolds. Despite the increased chemical modifications required in synthetic or 
hybrid scaffolds, the introduced biofunctionalizations can provide the opportunity to 
manipulate ECM mesh alignment, elasticity and swelling behavior, either by using static, 
or reversible precision chemistry reactions [68]. Hence, key events such as matrix 
stiffening can be simulated and precisely controlled [69,70]. 
 
Table 1. Advantages and disadvantages of different origin materials used for the production of scaffold-based 3D in vitro 
tumor models. 
Class Origin Examples Ref. Advantages Disadvantages 
Natural 
Mammalian 
Collagen [66,71] ▪ Contain in vivo similar 
domains (e.g., laminin, 
elastin, fibronectin) 
▪ Cellular adhesive 
properties 
▪ Recapitulate cells-ECM 
interactions present in 
vivo 
▪ Enzymatically 
degradable 
▪ Exact composition is 
unknown 
▪ Batch-to-batch variability 
▪ Limited level of control 
over matrix stiffness along 
time 
Matrigel
TM 
[72,73] 
Hyaluronan [74,75] 
Gelatin [76,77] 
Decellularized 
Matrix 
[78,79] 
Non-
mammalian 
Alginate [80,81] 
▪ Cell adhesion properties 
▪ High biocompatibility  
▪ Affordable 
▪ May require further 
modification to simulate in 
vivo tissues ECM 
components 
▪ Fabrication methods can 
be cytotoxic 
Chitosan [82,83] 
Silk-fibroin [84,85] 
Synthetic 
Polyethylene 
glycol (PEG) 
[86] 
▪ Good structural 
definition and chemically 
defined 
▪ Highly tunable 
mechanical properties 
▪ Lack ECM-mimicking 
domains 
▪ Require further 
modification to increase 
bioadhesion and 
biocompatibility 
▪ Degradation can result in 
Polylactic acid 
(PLA) 
[87,88] 
Poly-ε- 
caprolactone 
(PCL) 
[89,90] 
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Poly (lactic-co-
glycolic acid) 
PLGA 
[87,88] 
acidic by-products 
Hybrid 
Alginate-RGD [91,92] 
▪ Combine the ease of 
chemical modification 
and the presence of 
ECM-like domains  
▪ High-costs 
▪ Representation of few 
ECM components 
PEG-RGD [93,94] 
PEG-fibrinogen [95,96] 
 
These ECM mimetic scaffolds can be manufactured into diverse structures such as: 
(i) fibrillar porous meshes, (ii) porous and non-porous microstructures (including 
microparticles or microcapsules), and (iii) micro-patterned surfaces, via 3D bioprinting 
technologies [28,35,97–101]. The production methodologies of scaffold-based in vitro 
models have been extensively reviewed elsewhere [19,102–104]. The different materials 
that are used for the manufacture of these scaffolds are selected by their specific 
characteristics, such as the rate of biodegradation, biocompatibility, elasticity, ease of 
manipulation and similarity to tumor-specific ECM. In this context, the following sections 
will review the most commonly used materials for these models, starting with natural-
derived scaffolds and moving to synthetic and innovative combinatorial hybrid approaches 
used for correct ECM recapitulation.  
2.2.1. Natural materials-based Scaffolds  
From natural material-based scaffolds, the most commonly used hydrogel type for 
in vitro production of 3D-MCTS [28] is Matrigel
TM
, a hydrogel matrix comprised by 
basement-membrane extracts obtained from Engelbreth–Holm–Swarm mouse tumors [73]. 
The assembly of this hydrogel often requires laborious preparation, involving cooling of all 
the materials and thawing in ice to prevent premature polymerization, since the material is 
liquid at 4º C and jellifies above 10ºC [105]. When crosslinked, Matrigel
TM
 forms a 
randomly weaved mesh of fibers which withholds a large amount of fluid. Several types of 
Matrigel
TM
 formulations with various concentrations can be obtained commercially, such 
as those produced by Corning Life Sciences
®
, BD Biosciences
®
, and Trevigen
® 
[106]. This 
scaffold has been used to establish different types of 3D organoids (Figure 2A) and 3D 
spheroid (Figure 2B) models of various cancers, including those recognized by a highly 
aggressive progression such as pancreatic cancer [107].  
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Figure 2. Different types of 3D in vitro models that can be assembled by using MatrigelTM. (A) Cross section schematics 
of different types of assemblies to establish 3D pancreatic tumor organoids. (B) Cross section schematics of different 
types of assemblies to establish 3D cell cultures, namely cells in MatrigelTM and spheroids. (b1, c1, d1) Fluorescence 
microscopy micrographs of green fluorescent protein (GFP) expressing 4T1 breast cancer cells after 5 days of culture. 
(b1) Pre-coated 96 well plates with a 3D base comprised of MatrigelTM, where 4T1-GFP cells are cultured in normal cell 
culture medium. (c1) 4T1-GFP cells cultured in cell culture medium containing 2% MatrigelTM. (d1) Culture of 4T1-GFP 
cells in gel bed and gel containing medium, clear cellular aggregates are observable. Reproduced from Baker and co-
workers [107], and from Li and co-workers [108], with permission from Elsevier and Ivyspring International Publisher, 
respectively.  
 
Due to its in vivo origin, Matrigel
TM
-based scaffolds introduce ECM-specific 
signaling molecules and binding domains, such as laminin, collagen, elastin, entactin, 
fibronectin, fibrinogen and different growth factors (e.g., Epidermal growth factor (EGF), 
basic fibroblast growth factor (bFGF), Platelet-derived growth factor (PDGF)), among 
others [109]. Such bioactive components provide for example integrin and MMP binding 
sites, both of them imperative in tissue organization and cancer metastasis [60]. As a result 
of their origin, natural-based scaffolds exhibit similar structural interactions to those found 
in humans providing a suitable in vivo-like matrix where different cell lines can proliferate 
and acquire a stem-like phenotype [109,110]. However, due to the animal origin of 
Matrigel
TM
, this material also exhibits significant batch-to-batch variability [109], which 
results in low data reproducibility [27]. Furthermore, the complex and variable protein 
composition reduces the possibility to mimic tissue-specific ECM environments [27]. For 
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example, Matrigel
TM
 does not contain proper ratios of collagen type I or hyaluronan as 
those found in the matrix of in vivo tumors [105]. Moreover, it is important to emphasize 
that dynamic control over matrix stiffness in a dynamic mode is not possible [111]. 
However, it is possible to obtain Matrigel
TM
 formulations with different protein 
concentrations and thus manufacture gels with tunable elastic moduli. Such is an important 
aspect in 3D in vitro tumor models’ establishment, especially since matrix stiffness has 
been directly correlated with cells migration processes [112]. 
Other examples of natural based scaffolds commonly used for the assembly of 3D 
tumor models include collagen, hyaluronic acid, alginate, chitosan and silk fibroin 
hydrogels, as well as decellularized ECM. Most of them present, tunable mechanical 
properties, high biocompatibility and cell adhesive features [88]. The advantages and 
disadvantages of the use of these materials for assembly of 3D tumor models are 
summarized in Table 1. These materials have recently received increased focus as 
scaffolds for assembly of 3D tumor models in several reports [66,85,117–125,88,102–
104,113–116]. 
Collagen-based 3D models can be assembled either through physical or 
chemical\enzymatic crosslinking [126], leading to the establishment of a fibrillary scaffold. 
Collagen is the common constituent of the tumor microenvironment, being increasingly 
deposited during tumor progression for example in breast, lung, and colon cancers 
[127,128]. These natural 3D cell culture platforms contain key cellular adhesion domains 
and trigger signaling events capable of stimulating in vivo like morphology and gene 
expression, as demonstrated by Cheng and co-workers [66]. In this study, breast cancer 
cells (MCF-7) seeded on collagen porous scaffolds expressed high levels of pro-angiogenic 
factors (vascular endothelial growth factor (VEGF), bFGF and IL-8), matrix 
metalloproteinases (MMP-2, MMP-9). Additionally, cancer stem cells (CSC)-like 
populations (CD44
+
/CD24
-/low
) exhibiting increased epithelial-mesenchymal transition 
(EMT) markers expression (e.g., CT4A, SOX2, SOX4, JAG1) were detected [66]. 
Moreover, through the variation of protein content, or addition of synthetic cross-linking 
agents scaffolds stiffness, elasticity and fiber alignment of collagen gels and scaffolds can 
be varied to simulate matrix stiffening that occurs during disease progression [86]. As 
such, collagen hydrogels have been extensively used by various researchers to establish in 
vitro models for evaluation of EMT and cellular migration. For example, collagen has been 
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used to study breast cancer cell invasion through variations of fiber alignment and scaffold 
stiffness [71]. A study by Fraley and co-workers [117], analyzed the effect of distinct 
collagen gels crosslinking level, pore size and varying fibrillar alignment combinations on 
cancer cells mobility and ability to migrate in complex ECM mimetic matrices [117]. The 
main results demonstrated that according to fiber alignment the protrusion rate of cancer 
cells and their respective orientation was greatly influenced. Furthermore, the levels of 
matrix metalloproteinase activity and their respective inhibition were highly dependent on 
matrix structure and collagen density, mimicking the complexity of in vivo tumor-
associated matrix. This capacity to modulate cancer progression and invasion highlights 
the necessity of standardizing ECM mimetic microstructure characterization and 
composition. However, given the origin and composition of collagen, these in vitro 
scaffolds are prone to batch-to-batch variations, similar to those obtained with Matrigel
TM
. 
Other natural origin material that has been extensively investigated for assembly of 
3D in vitro tumor models is hyaluronic acid (HyA). HyA is a major glycosaminoglycan 
found ubiquitously in normal and malignant tissues ECM, being comprised of D-
glucuronic acid and D-N-acetylglucosamine residues [129]. HyA has been closely 
associated with cancer progression [130,131], and the presence of elevated quantities of 
HyA in the tumor stroma has been associated with poor patient outcome [132]. Given HyA 
importance in the TME a diverse array of studies has employed HyA-based scaffolds to 
establish 3D in vitro tumor models. Some of these studies take advantage of HyA unique 
chemical versatility that allows tailoring of its mechanical properties via precision 
chemical modification. One recent study that explores this possibility is that reported by 
Shen and co-workers [116], which developed a 3D scaffold based on acrylated hyaluronic 
acid hydrogels containing MMP-1 and MMP-2 sensitive peptides and bioadhesive RGD-
based domains for the culture of fibrosarcoma cells (HT-1080). Using varying 
concentrations of the MMP sensitive peptides as a bridging moiety between acrylated 
hyaluronic acid chains, hydrogels with diverse degrees of crosslinking and different 
mechanical properties were formulated (Figure 3A). The use of an MMP-responsive HyA 
hydrogel with different crosslinking degrees allowed to study fibrosarcoma cells pro-
angiogenic potential in different conditions that mimicked the native TME. An analysis of 
HT-1080 cells angiogenic sprouting potential demonstrated that in atmospheric conditions 
angiogenic induction only took place in soft and mediumly crosslinked HyA gels. 
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Whereas, the establishment of hypoxic conditions lead to sprouting even in highly dense 
HyA hydrogel networks (Figure 3F). 
 
Figure 3. Establishment of 3D in vitro tumor models based on Hyaluronic acid hydrogels. (A) Schematic representation 
of Acrylated HyA hydrogels demonstrating crosslinking through MMP sensitive peptide bridging and functionalization 
with RGD-containing peptides. (C, E) The concentration of MMP sensitive crosslinkers allowed the control over gels 
viscoelasticity. Fibrosarcoma cells were cultured in acrylated HyA gel with varying stiffness, and under atmospheric or 
hypoxic conditions. (B) Schematic representation of sprouting assay. (D) Fluorescence microscopy of lectin stained (red) 
endothelial cells infiltrating the hydrogel containing fibrosarcoma cells supplemented with Stromal cell-derived factor α 
(SDF-1α). (F) While under non-hypoxic conditions no penetration occurred in stiff hydrogels, in 1% oxygen sprouting 
was observable. Reproduced from Shen and co-workers [106], with permission from The Royal Society of Chemistry. 
Alginate, chitosan, and silk fibroin are examples of biopolymers derived of non-
mammalian origins that have also been used for establishing 3D in vitro tumor models. 
These materials present low immunogenicity and suitable biocompatibility for in vitro cell 
culture [88]. Alginate is derived from brown algae and formed by repeating units of α-L-
guluronic acid and β-D-mannuronic acid. Variations in the relative concentration of the 
two monomeric units produce changes in alginate physical and chemical properties, and 
the formation of gels with higher or lower water holding capacity and tunable porosity 
[133]. Alginate has been extensively used for cell encapsulation due to its capacity to 
rapidly crosslink under physiological conditions, easily forming a matrix that allows for 
medium and metabolite exchange [134,135]. However, it is important to mention that 
alginate possesses no cell adhesion properties, being often chemically modified with 
peptide-moieties or combined with other types of bioactive polymers [136].  
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 Chitosan is another biopolymer that has been extensively used to form porous 
scaffolds for cell culture and tissue engineering due to its biodegradable, non-
immunogenic and cationic nature which also promotes a facile functionalization with 
anionic molecules such as anionic glycosaminoglycans (e.g., HyA, heparan sulfate, 
heparin, chondroitin sulfate, keratan) [137]. The overall cationic charge of chitosan is 
attributed to its polymeric backbone which is comprised of glucosamine and N-
acetylglucosamine units [137]. Chitosan has been conjugated with other types of 
biopolymers (e.g., alginate, HyA) [138,139] or macromolecules (e.g., bioadhesion 
domains, signaling cytokines such as VEGF or bone morphogenetic protein 2 (BMP-2)) to 
form biofunctional 3D scaffolds for tumor in vitro modeling [140,141]. 
Combinations of both alginate and chitosan to produce 3D in vitro disease models 
are one of the most common. For example, in 2013, Kievit and co-workers [118], 
formulated a highly porous polyelectrolyte chitosan-alginate (CA) composite scaffold that 
was used to establish a 3D glioblastoma model to study cancer cells (U-87) migration. The 
manufactured CA scaffold presented well-defined and aligned-fibers with small diameters 
ranging from 200 nm to 1.1 µm. This promoted glioblastoma cells 3D migration and 
evidenced that this may be a cost-effective testing platform to screen for anti-metastatic 
therapies. Furthermore, later in 2016, Kievit and co-workers employed a similar scaffold to 
study glioblastoma cells interactions in diverse ECM mimetic or non-mimetic scenarios 
[119]. In this study, different CA scaffolds, namely those coated with poly-ε-caprolactone 
(PCL) (lacking bio-adhesion domains), or coated with HyA (allowing interaction with cell 
receptors – CD44/HyA interaction) were investigated (Figure 4G). The produced scaffolds 
where then used for glioblastoma 3D cell culture in mono or co-culture conditions, using 
astrocytes and endothelial cells to better mimic glioblastoma TME and its complex cell 
populations (Figure 4D, E, F) [119]. The obtained results showed that cells cultured in 
scaffolds coated with ECM mimetic HyA had an increased expression of stemness markers 
(CD44 and CD133) (Figure 4G, H).  
  
16 
 
 
Figure 4. Alginate-chitosan scaffolds formulated for establishment of glioblastoma 3D tumor models. (A) SEM images 
of different alginate-chitosan scaffolds namely: uncoated (CA), Hyaluronic acid (HyA) coated scaffolds, 
polycaprolactone (PCL) coated scaffolds. Scale bars in SEM images correspond to 500 µm in low magnification, and 20 
µm in high magnification. (C) Fourier-transform infrared spectroscopy (FTIR) characterization demonstrating the 
presence of the distinct coatings. (B) U-87 MG cells expressing RFP and cultured in the diverse platforms exhibited 
highly different morphologies derived from their ability to effectively interact with its surrounding hydrogel matrix. 
Moreover, in U-87 cells mono or co-cultures the level of CSC markers (G, H) increased significantly in HyA containing 
scaffolds. These results demonstrate both the ability of matrix-cell interactions and cell-cell communication (D, E, F) to 
influence tumor progression and establishment of CSCs-like phenotypes which resulted in increased expression stemness 
markers CD44 and CD133 as well as of Id1 a transcriptional regulator associated with apoptosis, angiogenesis, and 
neoplastic transformation. Adapted from Kievit and co-workers [119], with permission from The Royal Society of 
Chemistry. 
Silk fibroin, has also been extensively used for the development of 3D in vitro 
models, particularly for the study of cancer-to-bone metastasis [120,121], due to its 
resistance to protease degradation, as well as mechanical and cell adhesion properties (e.g., 
resultant from the naturally occurring RGD sequences of the fibroin protein). Adding to 
this silk fibroin can also be conjugated with different biomolecular cues (e.g., BMP-2, 
EGFR, SDF-1) [142,143]. To date, these scaffolds have been used for establishing in vitro 
3D models of primary tumors including those of prostate [85], and osteosarcoma [122]. 
Decellularized matrices (dECMs) such as those obtained from malignant/healthy 
tissues decellularization, or by through in vitro ECM production by 2D cultured cells [124] 
have been gaining increasing attention given their remarkable ability to provide native 
ECM components. However, the difficulty in producing such matrices in high-throughput 
compatible platforms, combined with the lack of structural and architectural control still 
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hinders decellularized matrices widespread use as scaffolds for 3D in vitro tumor models 
assembly. Hence, recent studies have been mainly focused on the production and 
characterization of highly reproducibly cell-derived dECMs [124], or in the production of 
disease-specific decellularized matrices [125]. Using this concept, Rijal and co-workers 
described the development of a 3D tissue matrix scaffold, obtained from decellularized 
breast tissues, that was processed either into hydrogel or porous scaffolds which 
recapitulate native tissue architecture and resilience [125]. The obtained dECMs allowed 
the culture of breast cancer cells in microenvironments similar to those found in mammary 
tissue. Moreover, by comparing cellular proliferation of MM231 breast cancer cells in 
diverse decellularized platforms and matrix extracts, the authors demonstrated the 
important role of disease-specific ECM. In this study, the results indicate that MM231 cells 
grown in decellularized tumor matrices exhibit the highest proliferation in comparison to 
MCF-10A breast fibroblasts. Interestingly, a pro-tumoral phenotype of T47D and BT474 
breast cancer cells tumoroids was obtained when anti-cancer drug-screening assays were 
performed in dECMs in comparison with other tested scaffolds (Collagen, Laminin rich 
ECM, PLGA) [125].  
2.2.2. Synthetic Materials based Scaffolds 
Alternatives to naturally derived scaffolds include synthetic, polymer-based, 
scaffolds that can be precisely manufactured to include ECM-mimicking cues and tweaked 
biophysical properties [103]. Several synthetic polymers exhibiting bioactive, 
biocompatible and biodegradable properties have been synthesized and reported in the 
literature in the recent decades, namely poly(ethylene glycol) (PEG), polylactic acid 
(PLA), poly(glycolic acid) (PGA), poly(lactic-co-glycolic acid) (PLGA) and poly-ε-
caprolactone (PCL) [5,133]. Overall, batch-to-batch variability and the lack of a precise 
control over scaffolds mechanical properties associated with natural scaffolds is eliminated 
when using well-defined, synthetic polymer-based scaffolds [144]. Moreover, when 
functionalized with bioactive molecules they serve both as bioinstructive and structural 
anchors until de novo matrix deposition by cancer and stromal cells occurs [28].  
However, cells cultured in purely synthetic platforms can proliferate devoid of 
tumor-like gene expression patterns, presenting inconsistent tumorigenicity, metastatic 
potential or drug-resistant phenotypes, when compared to those of in vivo tumors [28,145]. 
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Expectedly, such issues affect the production of robust tumor-mimicking 3D in vitro 
models. To overcome such drawbacks synthetic materials are often combined with other 
polymers such as polyvinyl alcohol (PVA), or with naturally derived biopolymers such as 
chitosan, hyaluronic acid or polydopamine, in order to attain more in vivo-like conditions 
[87,146,147]. 
2.2.3. Hybrid Scaffold Based Models 
The development of hybrid-based scaffolds for the assembly of 3D models is based 
on the incorporation of natural bioactive molecules (e.g., growth factors), and bioadhesive 
moieties (e.g., peptides), into the highly tunable/controllable matrix of synthetic scaffolds 
[88,133]. Synthetic materials can act as a ‘white-canvas’ and be conjugated with natural 
polymers such as fibrin [148], HyA [74], or specific bioactive molecules (e.g., BMP-2, 
RGD peptides). PEG and its derivatives (PEG-diacrylate) have been the most widely used 
synthetic polymers for conjugation with bioactive molecules and to ultimately form 3D 
biofunctional hybrid hydrogel scaffolds for cancer in vitro modeling. As demonstrated by 
Weiss and co-workers, PEG polymeric backbone was successfully functionalized with a 
peptide containing RGD domains [149], which resulted in increased cellular adhesive 
properties. In addition, MMP or plasmin-sensitive sequences have also been chemically 
coupled into PEG [114,144]. The inclusion of these bioactive moieties increased cellular 
interactions (e.g., cell-ECM and cell-cell), and mimicked tumor-ECM specific 
degradability [150]. One example of this strategy is the study performed by Roudsari and 
co-workers [151], in which PEG-based hydrogels, containing both MMP sensitive 
(GGGPQGIWGQGK), and cell adhesion (RGD) peptides, were used to co-culture lung 
adenocarcinoma cells (3445Q) with endothelial and pericyte vascular cells. These 
proteolytically-degradable models promoted tubule-like network formation guided by 
interactions with cancer cells and provided a suitable platform to study tumor neo-
vascularization.  
Compared to conventional natural or synthetic scaffold-based approaches, advanced 
hybrid scaffold-based 3D in vitro models represent more robust platforms in which several 
aspects of tumor progression can be recapitulated. In fact, hybrid scaffolds could allow to 
evaluate the role of specific ECM components in events such as metastasis [152] or cancer 
cells proliferation [153]. However, the manufacture of hybrid scaffold-based models 
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generally requires laborious production procedures, an important aspect that limits their 
use in high-throughput screening platforms [27]. Combination of hybrid scaffold-based 
methodologies with scaffold-free based techniques has provided novel and interesting 
platforms that can be used to modulate, with relative ease, several aspects of tumor 
progression, such as ECM deposition, metastasis, genetic drift and angiogenesis.  
Recapitulating the diverse facets of tumor progression in multifactorial hybrid-
based approaches, allows more predictive models to be obtained. A recent study by Hirt 
and co-workers, demonstrated the combination of bioreactor-based methodologies to 
develop a drug-screening model of colon cancer with HT-29 cells cultured in porous 
scaffolds under perfusion flow [154]. The model showed a high correlation with tumor 
xenografts regarding the testing of a cytotoxic compound (5-Fluorouracil), and a clinically 
effective compound (BCL-2 inhibitor ABT-199), with 2D cultures evidencing antagonistic 
responses [154].  
Other promising models have combined microfluidic platforms with collagen 
matrix hydrogels [155]. Microfluidic systems entail the use of micrometer-sized channels 
that open the possibility to produce 3D microtumor models under flow perfusion 
conditions [156]. Ultimately, scaffold-microfluidic combinations allow for a precise 
control of cancer cells growth by dynamically controlling cell culture media composition 
and manipulating drugs mass transfer via modification of liquid flow rate [157]. These 
characteristics make microfluidic systems ideal to perform angiogenesis, migration, or 
flow perfusion studies in the context of tumor perfusion and tumor invasion, EMT, cells 
dissemination and metastasis [28,158,159].  
From the abovementioned materials to assemble 3D tumor models for drug 
discovery, several have been translated into commercially available platforms in recent 
years. As summarized in table 2, these 3D in vitro cell culture tools take advantage of both 
scaffold-based and scaffold-free strategies to assemble 3D microtumors in TME 
mimicking environments and in a monotypic or heterotypic co-culture mode. Moreover, 
some of the most advanced platforms also allow to model nutrient flow dynamics and are 
amenable to screen anti-cancer candidates in high-throughput and high-content imaging 
settings (Table 2). 
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Table 2. Summary of commercially available technologies for establishment of 3D in vitro tumor models.  
Technology Product 
Name 
Description Services Ref 
Scaffold-Free 
 
Corning™ 
Ultra-Low 
Attachment 
Multiple Well 
Plates 
Forced Floating 3D spheroids formation 
via culture in round bottom, ultra-low 
attachment (ULA) multi-well plates 
- [160] 
GravityPLUS™ 
Hanging-drop based culture platform 
for 3D spheroids assembly and that 
uses a patented plate design which 
allows fast and user-friendly recovery 
of cultured microtumors 
Insphero® offers an on-
demand 3D spheroids 
development service 
using scaffold-free 
platforms 
[161] 
Nexcelom3D™ 
Ultra-low attachment (ULA) multi-well 
plates with flat or round bottom.  
- [162] 
Nunclon 
Sphera 
Surface™ 
Ultra-low attachment (ULA) multi-well 
plates with round bottom  
- [163] 
OncoPanel™ 
3D 
A drug profiling platform comprised of 
more than 100 types of cell line-based 
3D spheroid models suitable for drug-
screening and validation. The 
technology used for 3D spheroids 
assembly is not disclosed 
Provides a service of drug 
profiling, regarding 
penetration and anti-
proliferative screening in 
3D spheroid models for 
more than 18 different 
tissue types 
[164] 
Synthecon® 
Rotary Cell 
Culture 
Systems 
(RCCS) 
Rotary platforms based in NASA 
microgravity bioreactors, ideal for 3D 
spheroids culture under low-shear 
stress conditions 
- [20] 
Scaffold-
Based 
3D Insert™ 
Scaffolds with well-defined porous 
structures comprised either by PCL, 
polystyrene (PS), or PLGA and suitable 
for 3D microtissues assembly 
- 
[165,16
6] 
Advanced 
Biomatrix® 
Matrices and 
ECM Select® 
kits 
ECM Select® Array Kit Ultra-36 is an 
array of ECM-mimetic scaffolds based 
mainly in natural derived ECM 
constituents (e.g., silk fibroin, collagen 
types I, II, III and IV, hyaluronic acid, or 
adhesion proteins – vitronectin, 
fibronectin, laminin, etc) in which 3D 
tumor models can be established 
Provides an ECM platform 
in which cells can 
proliferate and be 
analyzed. This technology 
is useful for screening 
optimal matrix 
composition and 
mechanical properties 
that allow cells to grow in 
an environment that 
mimics in vivo conditions 
[167] 
AlgiMatrix® 
Alginate-based scaffold with a highly 
porous structure suitable for 3D cell 
culture and microtissues formation 
- [168] 
Alvetex® 
Highly porous PS scaffold suitable for 
3D cell culture and microtissues 
formation 
- [169] 
Cellusponge 
Disc shaped Collagen type I or 
Galactose-based scaffold that allow 
cells to be cultured in easy to use 3D 
environments 
- [170] 
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Cultrex® 
Murine basement membrane extract 
obtained from Engelbreth-Holm-Swarm 
tumors, available in reduced growth 
factor or concentrated growth factor 
form. This gel allows 3D cell culture in a 
bioactive environment 
- [171] 
Cytodex™ 
A group of crosslinked dextran matrix -
based particles, which can be used for 
3D cells expansion 
- [91,172] 
Geltrex® 
Soluble form of reduced growth factor 
basement membrane extract purified 
from murine Engelbreth-Holm-Swarm 
tumor 
- [173] 
HydroMatrix™ 
Peptide 
Hydrogel 
A self-assembled scaffold, based on 
synthetic peptide nanofibers. It offers 
precise control of 3D matrix 
architecture. Suitable for 3D cell 
culture and spheroids assembly 
- [174] 
HyStem® 
Hydrogels 
A diverse set of thiol-modified scaffolds 
that can be comprised of Hyaluronan 
(Glycosil®) or Hyaluran and heparin 
(Heprasil®). Offers the possibly of being 
combined with Thiol-reactive PEGDA 
crosslinkers (Extralink®) or Thiol-
modified collagen (Gelin-S®) 
- [175] 
Matrigel™ 
Engelbreth-Holm-Swarm sarcoma 
solubilized basement membrane 
extract. Available in both concentrated 
and reduced growth factor forms 
- [176] 
MaxGel™ 
Human extracellular matrix extract 
derived from human basement 
membrane. Suitable for 3D cell culture 
and invasion assays 
- 
[177,17
8] 
Qgel® Vials  
and Qgel® 
High-
throughput 
kits  
An extensive panel of specialized, PEG-
based ECM mimetics with well 
characterized mechanical properties 
and chemical composition, specifically 
tailored for tissue-specific cell lineages 
or primary cultures. The ECM-like 
matrices can be provided in modified 
96-well plates and/or high-throughput 
compatible kits, suitable for drug-
screening assays 
Qgel® provides a specific 
artificial matrix tailoring 
service with the objective 
of finding or designing 
scaffolds that better 
recapitulate tumor/tissue 
specific ECM 
[179] 
SeedEZ™ and 
GradientEZ™ 
Glass fiber-based disc or flower shaped 
bioinert scaffolds mainly used to study 
the influence of compound or growth 
factor gradients in 3D cultured cells 
- [180] 
SpongeCol® 
Type I collagen-based scaffold with 
cross-linked structure for increased 
mechanical strength and durability. 
Suitable for 3D cell culture and 
microtissue formation in a well-defined 
biodegradable micro-porous structure 
- [181] 
TrueGel3D™ 
Hydrogels 
Diverse array of scaffolds based in 
either PEG, PVA or dextran matrices, 
designed for 3D cell culture in tailored 
conditions i.e., fast (‘FAST-PVA’) or 
slowly (‘SLO-Dextran’) gelling gels, pH 
responsive gels, or gels tailored by the 
- [182] 
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addition of specific cell adhesion 
domains  
Hybrid – 
Bioreactor-
based 
Platforms 
 
3D Perfusion 
Bioreactor 
Combination of bioreactor technology 
with the 3D Biotek® PCL disc inserts for 
the formation of perfused microtissues 
- [160] 
3DKUBE™ 
3D cell scaffold-culture chambers 
which allows the establishment of 
independent scaffold-based cell 
cultures under perfusion 
- [161] 
Hybrid – 
Microfluidic-
based 
Platforms 
 
Ibidi™ µ-Slide 
III 3D 
Perfusion, 
A set of microfluidic devices capable of 
working in static or fluid perfusion 
conditions, in which cells included in 
3D scaffold-based models (e.g., 
Matrigel or other gel-based system) 
can be cultured. These platforms are 
suitable for simulating perfusion 
conditions, allowing for example drug 
administration under flow, chemotaxis 
and migration studies to be performed. 
The tumor models in chips/slides can 
be analyzed in real-time by 
microscopy-based analysis 
- 
[183,18
4] 
TissUse™ 
Organ-on-a-
Chip 
Organ-on-a-chip microfluidic devices 
that can accurately mimic physiological 
flow in microchannels. These can work 
in either free-circulation or closed-loop 
setup, allowing communication 
between reservoirs that can contain 3D 
scaffold-based models of tumor and 
healthy tissues developed by the user 
Provides a specific service 
of chip design and 
tailored healthy tissue 
organoid integration, 
oriented for drug 
screening 
[185] 
MIMETAS™ 
Organplate 
Models 
High-throughput compatible, organ-on-
a-chip platforms that allows insertion 
of scaffold-based 3D models (e.g., gel-
based), into close-loop microfluidic 
platforms. These platforms allow direct 
contact between scaffold containing 
sections and fluid containing channels 
by employing a patented phase guide 
system 
MIMETAS™ offers 
services of OrganPlate® 
model design for drug 
development, efficacy 
screening and toxicity 
studies in its facilities 
[186–
188] 
SynTumor™ 
3D Cancer 
Models 
Microfluidic devices engineered with 
tortuous channels with the aim of 
mimicking tumor-associated erratic 
microvasculature and transport across 
the vessel walls. 
These channels open into a central 
reservoir that can contain scaffold-
based 3D tumor models 
Provides real-time 
screening of tailor made 
tumor models. Services 
include target validation, 
compound screening, 
biomarkers analysis, 
adsorption, distribution, 
metabolism, toxicity and 
studies regarding 
mechanisms of action  
[189] 
*3D - Three-Dimensional; PCL - Poly-ε-caprolactone; PEG - Polyethylene Glycol; PEGDA - Poly Ethylene Glycol Diacrylate; PGA - Poly Glycolic Acid; PLGA - 
Poly Lactic-co-Glycolic Acid; PS – Polystyrene; PVA - Poly Vinyl Alcohol 
Although a significant number of commercial platforms has been developed, to date 
the majority of scaffold-based models, particularly those based on hydrogels, fail to 
achieve a precise control over 3D microtumors spherical morphology in a sense similar to 
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that obtained in 3D tumor spheroids assembled by scaffold-free approaches. However, 
despite the fact that 3D spheroids present reproducible morphological features and tunable 
size, the absence of pre-existing tumor ECM components also remains a significant 
drawback [19,190]. The following section will describe advanced technologies based on 
spherically structured 3D platforms that aim to bridge the gap between the lack of gel-
grown microtumors reproducible morphological control and the absence or pre-existing 
ECM components in 3D scaffold-free assembled spheroids.  
3. Spherically structured 3D In vitro Tumor Models 
Considering the specificities of the drug-screening process, namely the necessity of 
high-throughput, ease of analysis, reliability and predictable potential of the preclinical 
validation models [39,191], an ideal approach could require the combination of scaffold-
based models to represent ECM biochemical and mechanical complexity, along with the 
ease of analysis obtained from simple scaffold-free spherical models. Following the 
example of stem cells research in tissue engineering [17], such a combination could be 
achieved for example through the inclusion of microparticles containing specific ECM 
mimetic components. These combinations would allow the inclusion of TME specific 
matrix and cellular components into a spherical scaffold (Figure 5), thus leading to the 
formation of composite multicellular spheroids compatible with current analysis 
methodologies. An alternative methodology to the inclusion of microparticles would be the 
encapsulation of cancer cells inside hydrogel microcapsules [16]. Microencapsulation 
techniques have shown the capacity to confine cells and promote a reproducible spheroid 
growth, while providing ECM-like components that would otherwise be lacking 
[16,192,193]. Several spherical in vitro tumor mimicking cancer models have been 
developed so far, providing innovative platforms for the study of tumor biology and drug-
screening assays (Figure 5). Herein, microencapsulation and microparticle scaffold will be 
critically reviewed in light of recent reports. 
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Figure 5. Schematic representation of the diverse technologies used for assembly of spherically structured 3D in vitro 
tumor models. 
3.1. Microparticles for 3D Tumor Models Assembly 
As previously stated, 3D-MCTS are seen has golden standard in vitro models for 
performing drug-screening tests [194], due to their ability to correctly recapitulate several 
features of the tumor microenvironment, such as: (i) cell-cell interactions; (ii) matrix 
deposition; (iii) cell-ECM interactions; (iv) internal structure organization (responsible for 
hypoxia and consequently necrotic core formation) and (v) drug-resistance, stemming both 
from the acquisition of a resistant phenotype by continuous low drug dose stimulation, and 
drugs diffusional limitations in dense tumor masses [22]. These models provide a platform 
that can be easily assembled and facilitates high-throughput studies [195], in comparison 
with more complex scaffold or microfluidic-based models. However, as previously 
discussed in section 2.1, conventional spheroid-based models have inherent limitations that 
could be overcome by including biofunctional microparticles. 
Microparticles have been extensively applied in the field of tissue engineering 
mainly in four areas of application: (i) delivery of incorporated or surface-attached 
molecular cues or tethered protein into tissues or cell aggregates; (ii) reporting changes in 
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culture conditions; (iii) serving as scaffolds for cell attachment and providing necessary 
cues for cell differentiation or phenotype stimulation, and (iv) introduction or preservation 
of local targeted heterogeneity or homogeneity [17,196]. To date, most studies have 
explored of microparticles mainly for structural support of for providing molecular cues, 
with limited works exploring microparticles potential in the context of tumor modeling. 
Studies involving microparticles-based scaffolds for the production of in vitro tumor 
models [87,95,134,197–200], employing either non-modified synthetic polymers, or hybrid 
scaffolds such as the previously discussed PEG-Fibrinogen model, later developed by 
Pradhan and co-workers into the format of microspheres that allowed the assembly of 
spherical cancer models [95]. 
As mentioned, in comparison to scaffold based models, 3D-MCTS main limitation 
is the lack of a pre-existing ECM-like supporting structure. As a result, contrarily to what 
happens in vivo¸ the ECM will not be able to guide or influence cancer cells and stromal 
cells from the onset, ultimately failing to provide the necessary initial cues for 
characteristic cancer phenotypes to arise [201,202]. Consequently, the acquisition of 
phenotypes that do not resemble those found in vivo can be observed in certain culture 
settings. For instance, Brancato and co-workers [203], reported that for spheroids 
assembled either for cancer-associated fibroblasts (CAF) or normal fibroblasts, different 
cell metabolism, cell growth, matrix deposition rates and mechanical properties were 
observed when culturing cells with or without the support of porous gelatin microparticles 
[203]. Through the use of such microparticles, the authors were able to better replicate the 
functional and metabolic differences found in vivo between healthy and neoplastic tissues 
containing CAFs [203]. This study exemplifies that the introduction of microparticles into 
spheroid-based tumor models allows to surpass such limitations. 
Emerging reports have described the use of microparticle-based scaffolds as a 
means of introducing previously lacking ECM components into 3D-MCTS, promoting 
stem-like or multidrug resistance profiles [197,199,203]. The production methodologies 
for these microparticles mainly involve the application of modified double emulsion 
methods and sieving, with the combination of both techniques allowing a high yield of 
microparticles in the desired size ranges [95,197,198,200,203]. A significant body of 
knowledge on the methodologies to prepare polymer and hydrogel microparticles has been 
accumulated in the field of drug delivery systems in the past decades [204], and could be 
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transposed to support spherical cancer models production. One can envisage that simple 
compact particles to the surface of which cells can adhere, or porous micro- or 
macroparticle formulations (with enhanced surface area for cell attachment and adding 
additional volume for cell colonization) (Figure 5), can provide a structure capable of 
recapitulating aspects of the TME. Sahoo and co-workers [87], produced porous 
microparticles based scaffolds which allowed cells to interact with a semi-rigid or rigid 
ECM-like structure. The obtained PLGA/PLA microparticles exhibited diameters ranging 
from ~100-260 µm and consequently significant surface area for cell attachment. After a 
period of 5 days, microparticles were completely covered in cell layers, that ultimately 
formed a spherical aggregate in which compact cell-cell adhesion characteristics found in 
3D scaffold-free techniques were reproduced. This approach allows the establishment of 
3D-MCTS when used in combination forced-floating, hanging drop or stirring-based 
methodologies [87].  
In the context of particle porosity, the work of Kang and co-workers [200], 
established a cryopreservable tumor model of MCF-7 using PLGA microspheres with an 
average particle diameter of 393±5 μm, an exterior pore size ranging from 10-70 μm with 
intertwined porosity (Figure 6). The particles were used for cancer cells culture in stirred 
suspension bioreactors, achieved an elevated growth rate (2.8-fold cell expansion over 
seven days), increased resistance to doxorubicin when compared to 2D counterparts, as 
well as maintained viability and metabolic profiles after the process of cryopreservation. 
Moreover, the model exhibited increased effectiveness in establishing tumors on athymic 
female mice, with MCF-7 cells cultured on microspheres presenting a 4-fold increase in 
tumor formation [200]. 
 
Figure 6. (A, B) PLGA microspheres produced as a cryopreservable model SEM micrographs, presenting pores with 
suitable size for cells impregnation in the scaffold. (C) H&E staining of MCF-7 cells cultured on PLGA microspheres 
inside a spinner flask, image acquired at 5 days of culture. White and Black bars represent 100 µm. Adapted from Bae 
and co-workers [200], with permission from Elsevier. 
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So far, most studies involving tumor modeling produced polymeric microparticles 
as supporting scaffolds for assembling breast cancer cell spheroids, but mostly restricted to 
the MCF-7 lineage [95,197,198,200,203,205]. Several studies made use of Microparticles 
scaffolds as a mean of culturing breast cancer cells for measuring the cytotoxic effect of 
diverse pharmacological compounds such as doxorubicin, cisplatin, gemcitabine, 
paclitaxel, and tamoxifen [197,198,200]. In this context, Horning and co-workers [198], 
used a combination of PLA and chitosan to create microparticles with diameters of 160-
182 µm for culturing MCF-7 cells and evaluating its cytotoxicity profile against 
doxorubicin, paclitaxel, and tamoxifen [198]. The authors performed a comparison 
analysis between 2D and 3D models and observed that drug internalization was 
significantly delayed in the 3D model. (Figure 7). In fact, while in 3D models containing 
microparticles doxorubicin only reached the spheroid core region after 8h of incubation, in 
2D models such observations were visible within the first hour.  
 
 
Figure 7. Confocal images of doxorubicin penetration over several time periods (15 min, 1h, 4h, 6h, 8h and 24h) in both 
2-D monolayer cultures and 3-D of MCF-7 breast cancer cells, following incubation with 2.500 ng/ml of doxorubicin (in 
green). B and D columns of each section are enlarged areas of the images present in to their left. Analysis of doxorubicin 
penetration demonstrated slower penetration in MCF-7 spheroids when compared to 2D monolayers, taking almost 24 h 
to achieve the same level of doxorubicin inclusion in the 3D structures. Adapted from Horning and co-workers [198], 
with permission of American Chemical Society (ACS). 
The ability to recapitulate in vivo arrangements and expression patterns may pave 
the future for screening novel therapeutics targeting specific TME hallmarks. Another 
study by Brancato and co-workers improved on the previous porous gelatin microparticle-
based model of stroma through the addition of MCF-7 cancer cells. This breast cancer co-
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culture model containing porous gelatin Microparticles, was used to test a targeted 
nanoparticle drug delivery system [197]. A comparative analysis confirmed elevated 
expression of MMP-2 and other metalloproteinases in the 3D model versus 2D cultures, 
hence better mimicking in vivo overexpression by breast cancer cells in the TME. 
Interestingly, this enzymatic overexpression was effectively exploited via an enzyme-
responsive targeted delivery system, comprised by PLGA-PEG nanoparticles and a tumor 
targeting pro-drug activated by MMP-2 degradation. The obtained results evidenced 
increased specificity of targeting system in microparticles-based models, with the efficacy 
of the nanoparticles being confirmed through increased cytotoxicity in the 3D model 
(Figure 8) [197].  
 
Figure 8. Fluorescence microscopy (A, B, C) and RT-PCR (D) analysis of MMP-2 expression in both tumor mimicking 
(CAF/MCF-7) and normal breast tissue 3D spheroids (MCF-10A) containing porous gelatin microparticles (cell nuclei in 
blue, MMP2 protein in red; scale bar 75 µm). (F, G, J, K) Fluorescence microscopy analysis of doxorubicin penetration 
(green) (scale bar 50 µm); in tumor mimicking spheroids and healthy spheroids with (F, J) or without (G, K) MMP 
sensitive targeting nanocarrier particles. CAF/MCF-7 spheroids exhibited higher (C – left side) doxorubicin penetration 
especially when treated with MMP-2 sensitive doxorubicin carrying nanoparticles. (G, H) Alternatively, in normal tissue 
spheroids, no doxorubicin release was observed. Results demonstrate gelatin microparticles potential for mimicking in 
vivo overexpression of metalloproteinases. Adapted from Brancato and co-workers [197], with permission from Elsevier. 
Despite extensive implementation of microparticle-based scaffolds in tissue 
engineering applications, there is still a tremendous untapped potential for exploring these 
assemblies in the field of in vitro tumor modeling. In fact, most models containing 
microparticles merely focus their utilization as cell culture vehicles or for culture in 
bioreactors. Production of finely tuned microparticle structures using advanced 3D printing 
and micropatterning technologies [206], or through the use of flow-focusing microfluidic 
devices [207], could allow to study the role of specific signaling cues in in vitro expanded 
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malignant cells. These novel approaches may shed light upon biomolecules specific roles 
and enhance our capacity to modulate the TME in vitro. 
3.2. Microencapsulated 3D Models 
Encapsulation of cancer cells or spheroids is a promising strategy for tumor 
modeling that has received considerable attention in recent years [5]. Microencapsulation 
can serve as a mean of representing spatially defined ECM mimicking scaffolds. This 
strategy allows cancer and stromal cells to grow (in mono or co-cultures), and establish 
both cell-cell and cell-ECM interactions in a confined, yet, not fully isolated environment. 
Furthermore, the encapsulation of cancer cells, particularly in spherical-shaped, size-
controlled microcapsules with semi-permeable membranes, allows bidirectional diffusion 
of nutrients, oxygen, therapeutic compounds and low/medium molecular weight signaling 
molecules (e.g., growth factors and cytokines). In addition, microencapsulation can be 
employed to prevent the penetration of high molecular weight objects such as antibodies 
and immune cells [208], having been originally used as a tool for cell transplantation and 
immune isolation. In the field of tumor modeling, microencapsulation has been employed 
in a diverse set of ways that will be discussed in the following examples [16].  
The ability to restrain direct cellular contact makes microencapsulated 3D-MCTS as 
an ideal model to study the diverse paracrine interactions occurring in the TME between 
the different key cellular populations such as immune cells and mesenchymal stem cells 
[209]. This capacity of microencapsulated models was exploited by Yeung and co-workers 
[210], to study non-direct communication between neuroblastoma and bone-marrow 
derived mesenchymal stem cells. By using a collagen microsphere system, the authors 
demonstrated mesenchymal stem cells ability to promote neuroblastoma growth [210]. 
Such combinations of diverse cell populations in indirect contact can also be achieved in a 
hierarchically structured way, as demonstrated by the multilayered models produced by 
Fang and co-workers [192]. These authors manufactured hierarchically-assembled 
microencapsulated tumor models of prostate cancer cells (PKD1), and prostate cancer 
TME associated stroma cells (WPMY-1) in an alginate hydrogel. By separating the diverse 
cellular populations into different particle sub-layers, the authors achieved an ideal model 
in which to study the paracrine interactions established between both cell populations 
(Figure 9). 
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Figure 9. Formulation of multi-layer spherical tumor models for compartmentalized 3D co-culture. (A) Schematic 
representation of the double-layered 3D models containing diverse cellular populations, and their respective analysis 
through (B) optical contrast light microscopy of stromal cells growth in the inner core with an empty outer-layer (7 days), 
and (C) live dead analysis of cells cultured in the double-layered model show that cells remain viable for over 30 days. 
Adapted from Fang and co-workers [192], reproduced under Creative Commons License. 
In a recent study by Lu and co-workers [211], compartmentalized hydrogel microparticles 
containing ECM-mimetic scaffolds were produced through the combination of multi-
fluidic electrospray of hydrogel particles with ionic/thermal gelation mechanisms (Figure 
10). The ability to obtain compartmentalized platforms is important for several fields of 
tissue engineering and 3D in vitro disease models, a point which the authors demonstrated 
by utilizing the novel system to perform 3D cultures of small intestinal organoids, as well 
as tumor and hepatic microtissues. By using this platform, the authors were able to produce 
size-controlled microcapsules at a high rate (10 000 particles min
-1
), containing direct or 
indirect co-cultures of MDA-MB-231 breast cancer cells, MCF-10A normal mammary 
epithelial cells, and normal human lung fibroblasts (Figure 10Q, R). In culture, cells could 
communicate either by direct contact or via paracrine interactions, according to the 
compartmentalization settings. Furthermore, given the ability to control microgels size 
from 95 to 725 µm, the authors easily obtained encapsulated cultures with 600 µm of 
diameter and capable of recapitulating the hypoxic conditions seen in in vivo avascular 
solid tumors. The capacity of recapitulating direct and indirect interactions, the ability to 
represent both physical (hypoxic gradients) and biochemical (ECM composition) 
properties combined with the ability to sequentially retrieve cultured cells, makes this an 
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ideal platform for further studies on gene expression, cell-cell signaling, and drug 
screening. 
 
Figure 10. (A, F, K, P) Schematic representation of the diverse multi-fluidic geometries used for production of hydrogel 
microparticles containing (P, Q) or not (A, F, K) two distinct ECM cores (P, R). Fluorescence Microscopy images of 
double-layer (B, C, G, H) and triple-layer (L, M,) microparticles containing fluorescently labeled alginate (either green or 
red). (D-E, I-J, N-O) Fluorescence microscopy images of co-cultured cells (green cells: MDA-MB-231 expressing GFP; 
red cells: normal human lung fibroblasts expressing RFP; blue cells: MCF-10A stained with Hoechst. (Q, R) These 
microparticles allowed indirect co-culture of diverse cell populations in distinct ECM-like environments, such as co-
culture of MCF-10A cells in collagen (red), and MDA-MB-231 cells in Matrigel™ (green). Adapted from Lu and co-
workers [211], with permission from Royal Society of Chemistry (RSC). 
Layer-based microencapsulation can also be for the proliferation of key tumor sub-
populations as demonstrated by Rao and co-workers [212], for prostate cancer stem-like 
cells (PCa-CSCs). By manufacturing liquid core microcapsules with an alginate hydrogel 
shell, the authors were able to accelerate PCa-CSCs production from 10 days to 2 days. 
When compared to growth in ultra-low attachment plates, microencapsulated prostate 
spheroid models presented a higher degree of stem cell surface receptor markers and 
higher pluripotency, which combined with the rate of production, renders this platform 
suitable for the production of PCA-CSCs in vitro [212].  
On a different perspective, microencapsulation can also provide a platform for 
enhanced recovery of both cells and cell-secreted factors [213,214]. A study by Cui and 
co-workers [215], demonstrated the feasibility of easy cell recovery through thermal-
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dissociation of microcapsules incorporating HeLa cells which were readily recovered as 
aggregates under specific temperature conditions. Another study, by Huang and co-
workers [193], reported a microcapsule model formed by gelation of a newly discovered 
peptide for encapsulation of MCF-7 cells. The methodology employed for microcapsule 
formation allowed cells to be encapsulated at physiological pH and temperature, in 
minimum essential medium, decreasing cytotoxic effects sometimes associated with 
microencapsulation processes [16,216]. Through shear stress, caused by pipetting, the gel 
was easily converted back to its liquid form allowing recovery of breast cancer cells [193]. 
Furthermore, cytotoxicity assays with cisplatin revealed that the models were suitable for 
drug-screening assays, by allowing free penetration of the drug. Such ability to isolate 
specific cells further increases the capacity of studying genetic and phenotypic alterations 
in specific sub-sets of the cultured cells. In a recent study by Yang and co-workers [217], 
spherical alginate-based microcapsules were used to cultivate low passage human 
mucoepidermoid cells, and also to isolate angiogenesis-related molecules released from 
these cancer cells. The analysis of 3D cultures phenotypes and genotypes revealed a higher 
expression of pro-angiogenic genes and hypoxia associated factors in comparison to those 
obtained in standard 2D cultures [217]. 
Microencapsulation can also be exploited for the assembly of hierarchic 3D tumor 
models. In a recent report, Agarwal and co-workers [218], microencapsulated breast cancer 
cells (MCF-7) in collagen I and alginate core-shell semi-permeable microcapsules (~400 
µm) that served units for the bottom-up assembly of a 3D microtumor. This hierarchical 
model was able to promote de novo vasculature establishment and organization when 
encased under perfusion in a collagen I hydrogel containing human umbilical vein 
endothelial cells (HUVECs) and hADSCs (Figure 11B). This merged structure was then 
placed inside a microfluidic chip, being subjected to physiologic perfusion conditions. By 
introducing such physical and biochemical cues, through paracrine communication with 
encapsulated cancer cells, the authors effectively mimicked HUVECs vasculogenic 
morphogenesis. Furthermore, in vitro analysis revealed highly increased resistance to 
doxorubicin when compared to avascular and 2D models containing the same cellular 
ratios (4.7 and 139.5 times respectively) (Figure 11D). 
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Figure 11. (A) Schematic representation hierarchically structured, vascularized 3D breast cancer models. Cells were 
encapsulated in Alginate-Collagen microcapsules (~200 µm) by using a microfluidic chip, (C) being cultured for up to 10 
days with no loss of viability due to the radius of ~200 µm. (B) These microtumors were then assembled in a bottom-up 
approach into a vascularized tissue by encasing in a collagen I hydrogel in a perfusion microchip, containing HUVECs 
and adipose derived stem cells. (E) The combination of biological and physical interactions leads to de novo formation of 
functional vasculature mimicking the processes of angiogenesis seen in vivo. (D) This capacity noticeably contributed to 
a significant increase in models’ resistance Doxorubicin. Adapted from Agarwal and co-workers, [218], with permission 
from the American Chemical Society (ACS). 
Similarly, to microparticles, microcapsules can also serve as a technology for the 
inclusion of tumor ECM components. Several studies demonstrated that for neuroblastoma 
[210], lung [219] and breast [29,208,210,220] cancer microencapsulated spheroids 
establish cell-cell signaling interactions similar to those observed in vivo. Moreover, 
internal ECM matrix components deposition occurs inside the microcapsules, leading to 
increased resistance when compared to conventional 2D models. Such makes these 3D 
microencapsulated models possibly suitable for drug-screening assays and research in 
tumor drug resistance. Interestingly, microencapsulated 3D-MCTS models can mimic for 
example both solid tumor density [29], cell-matrix interactions, and the mechanical and 
physical pressures resultant from uncontrolled expansion of tumor masses, which can 
promote cancer metastasis and lead to profile alterations in cancer cells [216]. In fact, as 
demonstrated by Guzman and co-workers [221], depending on the elasticity of the chosen 
microcapsule, these can allow the study of the invasive processes carried out for example 
by invasive breast cancer [221] and other epithelial tumors [222], recreating the breaching 
of the involving basement membrane layer that surrounds the primary tumor site. 
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Furthermore, as elegantly demonstrated by Alessandri and co-workers [216], 
microcapsules can be used to study the buildup of intra-tumoral pressure, decurrent from 
the increasing of tumor mass generating increasing pressure on adjacent tissues and 
conversely compressing the tumor [223]. 
Microcapsule-encompassed spheroids are assembled through several 
methodologies, the most common of which being generation of liquid-core structures by 
employing microfluidic devices and hydrogel reticulation methods [29,208,216,224–226]. 
Frequently assembled microcapsules present diameters in the order of a few 100 µm to 500 
µm, an exception being the study produced by Pradhan and co-workers [205]. The authors 
assembled poly (ethylene glycol) diacrylate (PEGDA) milibeads through the usage of a 
single droplet emulsion technique in which the PEGDA droplets were crosslinked in oil 
solutions through a dual-photoinitiator system. The authors consistently created 
monodisperse milibeads with geometric diameters that ranged from 1671.24 ± 34.91 μm to 
3089.07 ± 55.58 μm (Figure 12) for encapsulating MCF-7 cells [205]. Moreover, the 
developed model achieved good cell-cell and cell-matrix adhesion, proliferation and 
establishment of extensive necrotic chore regions at day 5 of culture, accompanied by 
proliferative outer rims, akin to those characteristic to in vivo tumors (Figure 12G) [205]. 
 
Figure 12. Tumor mili-sized particles capable of recapitulating tumor conditions lead to the establishment of necrotic 
cores around 5 days of culture. Live cells are stained with a green fluorescent marker, while dead ones appear in red. 
Difference between day 0 (A, B, C) and 5 days of culture (E, F, G). Ultrastructure of tumor mili-sized beads without (H) 
and with (D) encapsulated tumor cells, as observed through SEM. Adapted from Pradhan and co-workers [205], with 
permission from Langmuir. 
Microfluidic-based approaches use flow-focusing, T-junction chips or more 
complex channel designs [16,194] to generate droplets of cell suspensions mixed with pre-
selected biocompatible polymers or hydrogels. In these strategies, encapsulation into 
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spherical structures is achieved by exposure to a crosslinking agent, such as calcium bath 
solutions or UV light, which triggers gelation and produces microcapsules containing the 
desired cells. Encapsulated cells assemble over time to form matrix-encapsulated spheroids 
capable of establishing both cell-cell and cell-matrix interactions [227]. An excellent 
example of such application is the formerly mentioned study by Alessandri and co-workers 
[216]. In this study, a model of colon carcinoma based on murine CT26 colon cancer cell 
line was assembled through a simple and highly reproducible method, based on a 
microfluidic co-extrusion chip assembled by co-centering three glass capillaries extruding 
sequentially cell solution, calcium free solution and alginate solution into a calcium bath 
(Figure 13) [216]. The authors were able to assemble highly elastic spherical 
microcapsules that acted as quantitative mechanical sensors to measure the internal 
pressure resultant from the expanding tumor cells. Moreover, the researchers found that 
peripheral cells inserted in the encapsulated model readily escaped the spheroid 
environment, while the spheroid invasive profile was not present in non-confinement 3D 
models (Figure 13I) [216]. 
 
Figure 13. Production of spherical alginate microcapsules for development of 3D tumor models. (A, B) Schematic of the 
process used to produce alginate microcapsules, and confocal micrographs after staining with dextran (B). CT26 cultured 
in alginate matrix (E, F) and in free-spheroid form (C, D). (H) 3D models were cryosectioned and analyzed through 
immunolabeling DAPI (blue), Ki-67 (magenta), and fibronectin (red). Magnified confocal microscopy image of the 
surface of a fixed spheroid after staining with phalloidin-Alexa 488 (Hot LUT, cyan) (H). After reaching confluence both 
confined and control spheroids (G) were inserted into a collagen-based scaffold to access invasion capacity; (I) After 48 h 
cultured cells in confined models started to invade collagen matrix while freely formed spheroids retained their spherical 
shape. Scale bars: B=50 μm; C, D, E, and F=100 μm; G=50 μm; H=10 μm; I=100 μm. Adapted from Alessandri and co-
workers [216], with permission from Proceedings of the National Academy of Sciences of the United States of America 
(PNAS). 
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Additional approaches to microcapsule production consist in the utilization of 
coaxial electrospray-based encapsulation, or alternatively, aerosol-based 
microencapsulation [226]. Leong and co-workers [226], demonstrated the feasibility of 
microencapsulating keratocytes (HaCaT) and cancer cells of oral squamous cell carcinoma 
(ORL-48) inside alginate microcapsules polymerized in a calcium bath. Produced 
microtissues were capable of self-arranging into spheroids inside the alginate 
microcapsules, remaining viable until after 16 days of culture. Other commonly employed 
techniques for microcapsule production involve simple procedures such as emulsion 
technique-based microencapsulation, or syringe pump extrusion and micromolding [16]. 
The work developed by Lee and co-workers [225], is an excellent example of the latter 
technique. In this study, the authors used diffusion-mediated encapsulation, performed in 
PDMS-micromolds where hepatocarcinoma spheroids were previously assembled. Such 
spheroids were subjected to posterior deposition of an encapsulating alginate hydrogel 
through nano-porous membranes, which allow a control over crosslinking agents 
deposition rates [225]. Lastly, 3D bio-printing has also been used by Xu and co-workers 
[228], to produce high-throughput automated encapsulation of ovarian cancer cells and 
fibroblast co-culture droplets in Matrigel™. This approach allows the study of co-culture 
interactions in diverse settings due to high control over initial cell density and spatial 
arrangement of the patterned structure of the model, paving the way for the development of 
more complex and precise spherical scaffold-based tumor models to be generated. 
Identically microparticles, microcapsules can be used as a means of incorporating 
specific ECM mimetic components allowing the establishment of in vivo like interactions 
between internalized cells and tumor ECM as shown by Xu and co-workers [219]. In this 
study, the authors encapsulated A549 cells in a gelatin and glycosaminoglycan matrix 
modified with VEGF, bFGF, and a laminin peptide to improve cell adhesion, in an attempt 
to substitute the commonly used Matrigel™ and establishing an improved xenograft model 
using enriched 3D encapsulated lung cancer cells in vivo. The results showed that the 
functionalized gelatin membrane was comparable to Matrigel
TM
-based models, but allowed 
a complete control over initial matrix composition [219]. 
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3.3 Design parameters for fabrication of Spherically Structured 3D 
Tumor Models  
Establishing reproducible and easy to analyze spherically structured in vitro 3D 
tumor models containing bioinstructive tumor-ECM moieties requires the manipulation of 
key parameters including: (i) the inclusion of multiple cellular components of the tumor 
stroma (e.g., fibroblasts, mesenchymal stem cells, adipocytes, etc) and their cell-cell ratios; 
(ii) type of culture medium; (iii) scaffolds biodegradability; (iv) selection and degree of 
functionalization of bioactive ECM-mimetics; (v) 3D spheroids size, as this parameter 
influences the formation of the characteristic necrotic core of solid tumors; and (vi) 
microparticles/microcapsules porosity due to its role in nutrients and cells diffusion 
through the scaffolds. Moreover, other parameters such as tumor ECM mechanical and 
viscoelastic properties must be controlled to closely mimic those of the native diseased 
tissues. This one of the most important parameters since as demonstrated by Alessandri 
and co-workers [216], the elasticity of the matrix in which cells adhere can influence the 
establishment of a pro-metastatic phenotype, simulating the pressure exerted by 
surrounding tissues over the tumor mass [222]. Careful consideration must also be given to 
the manufacturing processes required for the fabrication of spherical 3D models based on 
microparticles or microcapsules, since the crosslinking processes might require cells 
exposure into deleterious, non-physiological conditions such as acidic/basic pH [216], 
organic solvents, or exposure to high-intensity UV light during photo-crosslinking 
reactions, all of these resulting in loss of cellular viability[16]. 
4. Conclusions and Future Perspective 
The need for expediting drug research both at the preclinical validation level and 
discovery of novel targets is crucial for the management of currently incurable diseases 
such as cancer. Research regarding the development of novel 3D in vitro models is 
increasingly contributing to this goal by providing innovative platforms capable of 
efficiently, predictively, and robustly mimicking in vitro the complex in vivo reality of the 
TME in what regards its cellular and ECM components. Among the vast array of 3D cell 
culture methodologies that have been developed to date for in vitro tumor modeling, 3D 
spheroid-based models are the most promising regarding the production of high-
throughput usable and affordable tumor mimetics. Microencapsulation and microparticle-
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based production technologies are capable of recreating complex cell-cell, mechanical and 
physiological characteristics that recapitulate in vivo solid tumors, at both the cellular and 
ECM level. These are highly valuable characteristics since standard 3D spheroid models 
lack correct ECM representation and confinement of soluble mediators (e.g., growth 
factors, cytokines) in controlled environments such as those found in human tumors niche.  
Overall, there is a tremendous potential for improving 3D spheroid-based drug 
screening platforms by combining the knowledge acquired in scaffold-based 
methodologies with microencapsulation or microparticle inclusion techniques to form 
spherical microtumor constructs compatible with already implemented analysis 
methodologies (e.g., high-content imaging) [16,17]. Such complex hybrid spherical 
approaches to 3D tumor modeling, combined with the implementation of co-culture 
models have the potential to mimic a plethora of features that extend beyond the capacity 
of conventional 3D-MCTS. The inclusion of populations such as immune-cells (e.g., 
macrophages, dendritic cells, T-cells etc), adipocytes, mesenchymal stem cells, endothelial 
cells and tumor stroma associated fibroblasts (CAFs) is paramount importance for a full 
TME recapitulation. We envision that making efforts towards the inclusion of multiple 
cells in spherically structured compartmentalized-like capsular models could allow the 
study of paracrine signaling and provide platforms for discovery of innovative immune-
oncological therapeutics. Moreover, microencapsulation provides the means of studying in 
detail both direct and indirect cell-cell and cell-matrix interactions found in the TME. A 
deeper knowledge about such crosstalk and events will open the opportunity to develop 
more advanced therapies that for example inhibit the process of tissue invasion and 
metastasis. Given that the vast majority of cancer-related deaths is associated with 
metastasis [229], from a therapeutic perspective, metastasis inhibition will open a new 
window of opportunity to significantly increase patient survival rates past 5 years. 
In a future perspective, the nature of 3D spheroid models and the unique features 
provided by microencapsulation and microparticle technologies could also be combined 
with dynamic bioreactor-based culturing technologies to provide an added layer of in vivo-
like conditions under dynamic flow conditions. Moreover, further improvements to hybrid 
spherical 3D tumor models are expected upon their combination with advanced organ-on-
a-chip platforms and through the implementation of methodologies already used in the 
field of tissue engineering such as those related to cells microencapsulation cells-
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microparticle adhesion, as well as the formation of healthy tissue surrogate constructs. 
These healthy tissue constructs could be used to study the metastasis process from 3D 
tumor models in multi-compartment organ-on-a-chip platforms. This is envisioned to 
contribute to a faster discovery of more effective anti-cancer and anti-metastatic 
compounds or compound combinations.  
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Statement of Significance: The ability to correctly mimic the complexity of the 
tumor microenvironment in vitro is a key aspect for the development of evermore realistic 
in vitro models for drug-screening and fundamental cancer biology studies. In this regard, 
conventional spheroid-based 3D tumor models, combined with spherically structured 
biomaterials, opens the opportunity to precisely recapitulate complex cell-extracellular 
matrix interactions and tumor compartmentalization. This review provides an in-depth 
focus on current developments regarding spherically structured scaffolds engineered into 
in vitro 3D tumor models, and discusses future advances toward all-encompassing 
platforms that may provide an improved in vitro/in vivo correlation in a foreseeable future. 
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Table 2. Advantages and disadvantages of different origin materials used for the production of scaffold-based 3D in vitro 
tumor models. 
Class Origin Examples Ref. Advantages Disadvantages 
Natural 
Mammalian 
Collagen [66,71] ▪ Contain in vivo similar 
domains (e.g., laminin, 
elastin, fibronectin) 
▪ Cellular adhesive 
properties 
▪ Recapitulate cells-ECM 
interactions present in 
vivo 
▪ Enzymatically 
degradable 
▪ Exact composition is 
unknown 
▪ Batch-to-batch variability 
▪ Limited level of control 
over matrix stiffness along 
time 
Matrigel
TM 
[72,73] 
Hyaluronan [74,75] 
Gelatin [76,77] 
Decellularized 
Matrix 
[78,79] 
Non-
mammalian 
Alginate [80,81] 
▪ Cell adhesion properties 
▪ High biocompatibility  
▪ Affordable 
▪ May require further 
modification to simulate in 
vivo tissues ECM 
components 
▪ Fabrication methods can 
be cytotoxic 
Chitosan [82,83] 
Silk-fibroin [84,85] 
Synthetic 
Polyethylene 
glycol (PEG) 
[86] 
▪ Good structural 
definition and chemically 
defined 
▪ Highly tunable 
mechanical properties 
▪ Lack ECM-mimicking 
domains 
▪ Require further 
modification to increase 
bioadhesion and 
biocompatibility 
▪ Degradation can result in 
acidic by-products 
Polylactic acid 
(PLA) 
[87,88] 
Poly-ε- 
caprolactone 
(PCL) 
[89,90] 
Poly (lactic-co-
glycolic acid) 
PLGA 
[87,88] 
Hybrid 
Alginate-RGD [91,92] 
▪ Combine the ease of 
chemical modification 
and the presence of 
ECM-like domains  
▪ High-costs 
▪ Representation of few 
ECM components 
PEG-RGD [93,94] 
PEG-fibrinogen [95,96] 
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Table 2. Summary of commercially available technologies for establishment of 3D in vitro tumor models.  
Technology Product 
Name 
Description Services Ref 
Scaffold-Free 
 
Corning™ 
Ultra-Low 
Attachment 
Multiple Well 
Plates 
Forced Floating 3D spheroids formation 
via culture in round bottom, ultra-low 
attachment (ULA) multi-well plates 
- [160] 
GravityPLUS™ 
Hanging-drop based culture platform 
for 3D spheroids assembly and that 
uses a patented plate design which 
allows fast and user-friendly recovery 
of cultured microtumors 
Insphero® offers an on-
demand 3D spheroids 
development service 
using scaffold-free 
platforms 
[161] 
Nexcelom3D™ 
Ultra-low attachment (ULA) multi-well 
plates with flat or round bottom.  
- [162] 
Nunclon 
Sphera 
Surface™ 
Ultra-low attachment (ULA) multi-well 
plates with round bottom  
- [163] 
OncoPanel™ 
3D 
A drug profiling platform comprised of 
more than 100 types of cell line-based 
3D spheroid models suitable for drug-
screening and validation. The 
technology used for 3D spheroids 
assembly is not disclosed 
Provides a service of drug 
profiling, regarding 
penetration and anti-
proliferative screening in 
3D spheroid models for 
more than 18 different 
tissue types 
[164] 
Synthecon® 
Rotary Cell 
Culture 
Systems 
(RCCS) 
Rotary platforms based in NASA 
microgravity bioreactors, ideal for 3D 
spheroids culture under low-shear 
stress conditions 
- [20] 
Scaffold-
Based 
3D Insert™ 
Scaffolds with well-defined porous 
structures comprised either by PCL, 
polystyrene (PS), or PLGA and suitable 
for 3D microtissues assembly 
- 
[165,16
6] 
Advanced 
Biomatrix® 
Matrices and 
ECM Select® 
kits 
ECM Select® Array Kit Ultra-36 is an 
array of ECM-mimetic scaffolds based 
mainly in natural derived ECM 
constituents (e.g., silk fibroin, collagen 
types I, II, III and IV, hyaluronic acid, or 
adhesion proteins – vitronectin, 
fibronectin, laminin, etc) in which 3D 
tumor models can be established 
Provides an ECM platform 
in which cells can 
proliferate and be 
analyzed. This technology 
is useful for screening 
optimal matrix 
composition and 
mechanical properties 
that allow cells to grow in 
an environment that 
mimics in vivo conditions 
[167] 
AlgiMatrix® 
Alginate-based scaffold with a highly 
porous structure suitable for 3D cell 
culture and microtissues formation 
- [168] 
Alvetex® 
Highly porous PS scaffold suitable for 
3D cell culture and microtissues 
formation 
- [169] 
Cellusponge 
Disc shaped Collagen type I or 
Galactose-based scaffold that allow 
cells to be cultured in easy to use 3D 
- [170] 
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environments 
Cultrex® 
Murine basement membrane extract 
obtained from Engelbreth-Holm-Swarm 
tumors, available in reduced growth 
factor or concentrated growth factor 
form. This gel allows 3D cell culture in a 
bioactive environment 
- [171] 
Cytodex™ 
A group of crosslinked dextran matrix -
based particles, which can be used for 
3D cells expansion 
- [91,172] 
Geltrex® 
Soluble form of reduced growth factor 
basement membrane extract purified 
from murine Engelbreth-Holm-Swarm 
tumor 
- [173] 
HydroMatrix™ 
Peptide 
Hydrogel 
A self-assembled scaffold, based on 
synthetic peptide nanofibers. It offers 
precise control of 3D matrix 
architecture. Suitable for 3D cell 
culture and spheroids assembly 
- [174] 
HyStem® 
Hydrogels 
A diverse set of thiol-modified scaffolds 
that can be comprised of Hyaluronan 
(Glycosil®) or Hyaluran and heparin 
(Heprasil®). Offers the possibly of being 
combined with Thiol-reactive PEGDA 
crosslinkers (Extralink®) or Thiol-
modified collagen (Gelin-S®) 
- [175] 
Matrigel™ 
Engelbreth-Holm-Swarm sarcoma 
solubilized basement membrane 
extract. Available in both concentrated 
and reduced growth factor forms 
- [176] 
MaxGel™ 
Human extracellular matrix extract 
derived from human basement 
membrane. Suitable for 3D cell culture 
and invasion assays 
- 
[177,17
8] 
Qgel® Vials  
and Qgel® 
High-
throughput 
kits  
An extensive panel of specialized, PEG-
based ECM mimetics with well 
characterized mechanical properties 
and chemical composition, specifically 
tailored for tissue-specific cell lineages 
or primary cultures. The ECM-like 
matrices can be provided in modified 
96-well plates and/or high-throughput 
compatible kits, suitable for drug-
screening assays 
Qgel® provides a specific 
artificial matrix tailoring 
service with the objective 
of finding or designing 
scaffolds that better 
recapitulate tumor/tissue 
specific ECM 
[179] 
SeedEZ™ and 
GradientEZ™ 
Glass fiber-based disc or flower shaped 
bioinert scaffolds mainly used to study 
the influence of compound or growth 
factor gradients in 3D cultured cells 
- [180] 
SpongeCol® 
Type I collagen-based scaffold with 
cross-linked structure for increased 
mechanical strength and durability. 
Suitable for 3D cell culture and 
microtissue formation in a well-defined 
biodegradable micro-porous structure 
- [181] 
TrueGel3D™ 
Hydrogels 
Diverse array of scaffolds based in 
either PEG, PVA or dextran matrices, 
designed for 3D cell culture in tailored 
conditions i.e., fast (‘FAST-PVA’) or 
slowly (‘SLO-Dextran’) gelling gels, pH 
- [182] 
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responsive gels, or gels tailored by the 
addition of specific cell adhesion 
domains  
Hybrid – 
Bioreactor-
based 
Platforms 
 
3D Perfusion 
Bioreactor 
Combination of bioreactor technology 
with the 3D Biotek® PCL disc inserts for 
the formation of perfused microtissues 
- [160] 
3DKUBE™ 
3D cell scaffold-culture chambers 
which allows the establishment of 
independent scaffold-based cell 
cultures under perfusion 
- [161] 
Hybrid – 
Microfluidic-
based 
Platforms 
 
Ibidi™ µ-Slide 
III 3D 
Perfusion, 
A set of microfluidic devices capable of 
working in static or fluid perfusion 
conditions, in which cells included in 
3D scaffold-based models (e.g., 
Matrigel or other gel-based system) 
can be cultured. These platforms are 
suitable for simulating perfusion 
conditions, allowing for example drug 
administration under flow, chemotaxis 
and migration studies to be performed. 
The tumor models in chips/slides can 
be analyzed in real-time by 
microscopy-based analysis 
- 
[183,18
4] 
TissUse™ 
Organ-on-a-
Chip 
Organ-on-a-chip microfluidic devices 
that can accurately mimic physiological 
flow in microchannels. These can work 
in either free-circulation or closed-loop 
setup, allowing communication 
between reservoirs that can contain 3D 
scaffold-based models of tumor and 
healthy tissues developed by the user 
Provides a specific service 
of chip design and 
tailored healthy tissue 
organoid integration, 
oriented for drug 
screening 
[185] 
MIMETAS™ 
Organplate 
Models 
High-throughput compatible, organ-on-
a-chip platforms that allows insertion 
of scaffold-based 3D models (e.g., gel-
based), into close-loop microfluidic 
platforms. These platforms allow direct 
contact between scaffold containing 
sections and fluid containing channels 
by employing a patented phase guide 
system 
MIMETAS™ offers 
services of OrganPlate® 
model design for drug 
development, efficacy 
screening and toxicity 
studies in its facilities 
[186–
188] 
SynTumor™ 
3D Cancer 
Models 
Microfluidic devices engineered with 
tortuous channels with the aim of 
mimicking tumor-associated erratic 
microvasculature and transport across 
the vessel walls. 
These channels open into a central 
reservoir that can contain scaffold-
based 3D tumor models 
Provides real-time 
screening of tailor made 
tumor models. Services 
include target validation, 
compound screening, 
biomarkers analysis, 
adsorption, distribution, 
metabolism, toxicity and 
studies regarding 
mechanisms of action  
[189] 
*3D - Three-Dimensional; PCL - Poly-ε-caprolactone; PEG - Polyethylene Glycol; PEGDA - Poly Ethylene Glycol Diacrylate; PGA - Poly Glycolic Acid; PLGA - 
Poly Lactic-co-Glycolic Acid; PS – Polystyrene; PVA - Poly Vinyl Alcohol 
 
 
 
